Welcome to Storyflo Daily Biotech. I'm Bea.
Today's reading is a Labiotech.eu slate — five pieces that together paint a tidy picture of where European biotech investment, modality science, and process engineering are concentrating right now.
The lead is Labiotech.eu's roundup of the eight Swedish companies spearheading the country's biotech scene in 2026. Sweden has quietly become one of the more interesting European life-sciences clusters — Karolinska, Uppsala, and the Lund-Malmö belt feeding a deeper bench than the headcount suggests. Labiotech's eight-name list is worth working through if you're sourcing deals or partnerships in the Nordics; the publication frames it as a sector that "continues to grow" rather than a sudden breakout, which matches the on-the-ground reality.
Modality piece of the day, also from Labiotech.eu: the rise of trispecific antibodies. The framing is that trispecifics are the industry's next big bet after bispecifics — adding a third binding domain to engage two tumor targets plus a T-cell effector simultaneously, or to combine targeting with checkpoint relief. Labiotech notes strong cross-industry interest, which tracks with what we're seeing in licensing-deal flow. If your bispecific thesis is mature, this is the natural next step to underwrite.
On the manufacturing side, Labiotech.eu has a guest piece with Dominic Clark, VP of Technical Operations for IntegriCell at Cryoport Systems, on cell-therapy supply chains. The argument is the one cell-therapy operators keep relearning the hard way: freeze variability — not the science — is what most often kills a program at scale. Building cryogenic discipline in from the start of clinical development, rather than retrofitting it for commercial, is the difference between a launch and a recall.
A clinical piece, also Labiotech: new antidepressants targeting treatment-resistant depression. The publication's frame is the gap between SSRI-era response rates and what newer mechanisms — ketamine-derived, psychedelic-assisted, fast-acting glutamatergic — can deliver in the TRD population specifically. Useful refresh if you've been out of the CNS market for a few cycles.
And to close, a Labiotech process piece on contamination control in CO2 shaking workflows — specifically the role of incubator-shaker sterilization validation in suspension cell culture. Niche, but if you're running a CDMO or scaling suspension at all, the cost of a contamination event is large enough to make the read worth it.
That's your Storyflo Daily Biotech. Sources in the notes. Bea out.
